Medicus Pharma Ltd. submitted an optimized Phase 2 clinical study protocol (ANT‑2111‑02) to the U.S. Food and Drug Administration for its investigational GnRH antagonist Teverelix, which is being developed to prevent recurrent acute urinary retention in men with benign prostatic hyperplasia.
The new protocol reduces the planned sample size to roughly 126 patients across the United States and Europe, a three‑fold reduction from the original design. It is a randomized, double‑blind, single‑dose, four‑arm study that will run for 52 weeks, with a 28‑week treatment period followed by a 24‑week follow‑up. The primary endpoint is the percent change in total prostate volume at week 12, while secondary endpoints include maximum urine flow rate, post‑void residual volume, and recurrence of acute urinary retention. An interim analysis will be conducted after about 50 % of participants reach the week‑12 assessment to inform dose selection, route optimization, and the design of a potential Phase 3 study.
Medicus Pharma’s financial results for the year ended December 31 2025 show a net loss of $35.4 million and cash and cash equivalents of $8.7 million. The company reported the same cash balance and no long‑term debt as of the second quarter of 2026, underscoring its limited liquidity and the importance of capital‑efficient development strategies.
Executive Chairman and CEO Dr. Raza Bokhari said the refined study design reflects a more capital‑efficient development strategy intended to accelerate Teverelix’s path to commercialization. He added, 'By focusing on clear pharmacodynamic endpoints and incorporating an interim analysis designed to inform subsequent clinical development, we believe Teverelix can generate actionable clinical data more rapidly, enabling earlier strategic engagement and potential partnering opportunities.'
The streamlined protocol is a key step in reducing development costs and shortening the timeline to generate data that can support regulatory submissions and partnership discussions. For a clinical‑stage company with limited cash, the ability to obtain robust efficacy and safety data from a smaller, more focused study is critical to maintaining financial viability and attracting potential collaborators.
Teverelix targets an addressable market of approximately $2 billion for AURr prevention and an additional $6 billion for advanced prostate cancer patients with high cardiovascular risk. The company’s focus on a GnRH antagonist that avoids the initial flare associated with agonists positions Teverelix as a potentially differentiated therapy in a market that currently lacks approved pharmacologic prevention options. Medicus Pharma is also advancing its SkinJect platform and integrating AI‑driven clinical development capabilities, further supporting its pipeline and strategic positioning.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.